NEW YORK, May 5, 2014 /PRNewswire/ -- As morcellator lawsuits (http://www.gynecaremorcellatorlawsuit.com/) filed on behalf of women whose cancer was allegedly spread by the use of power morcellators during uterine surgeries begin to be filed, Bernstein Liebhard LLP notes that a petition at Change.org is calling on federal regulators to ban the use of the devices for fibroid removals. According to a report from CBS News in Boston, a Massachusetts woman and her husband started the petition after she was diagnosed with stage four leiomyosarcoma, a rare but aggressive form of uterine cancer, following a morcellation procedure she underwent last year to remove fibroids.
"Our Firm is starting to hear from women who received a similar diagnosis following hysterectomies and fibroid removals that involved the use of a power morcellator," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering hysterectomy cancer lawsuit reviews to women who suffered uterine sarcoma or other cancers allegedly associated with power morcellation.
Power Morcellator Lawsuits
A power morcellator is used during robotic hysterectomies and other minimally invasive uterine surgeries to cut tissue into small pieces so that it can be removed from the body through a small abdominal incision. On April 17th, the U.S. Food & Drug Administration (FDA) issued an alert discouraging the use of the technology in hysterectomies and myomectomies for fibroid removal after a review indicated that power morcellation can promote the spread of undiagnosed uterine sarcomas beyond the uterus. Roughly 1 in 350 women who undergo fibroid removal may also suffer from undiagnosed uterine cancers, the FDA said.
In the wake of the FDA's alert, Johnson & Johnson announced it would suspend sales of several power morcellators marketed by its Ethicon, Inc. unit pending further guidance from the FDA. A number of hospitals, including Brigham and Women's Hospital in Boston and the Cleveland Clinic, have also suspended these procedures until the agency provides further clarification. That could come later this summer, as the FDA is planning to hold an advisory panel meeting to further investigate the matter.
In the meantime, court documents indicate that a number of power morcellator lawsuits are already pending in U.S. courts. On May 1st, one such lawsuit was filed in the U.S. District Court, Western District of New York on behalf of a woman who also blames the use of a power morcellator for the spread of leiomyosarcoma in her abdominal cavity. The complaint names Ethicon Endo Surgery, Inc. and Ethicon Women's Health and Urology as defendants. (Case 6:14-cv-06218)
In February, the husband of a 53-year-old woman who died from uterine cancer less than a year after she underwent power morcellation filed a hysterectomy cancer lawsuit in the U.S. District Court, Eastern District of Pennsylvania. In addition to Ethicon, the complaint names Blue Endo, and Lina Medical, among others, as defendants. (Case No. 14 5557).
Women who were diagnosed with uterine sarcoma, leiomyosarcoma, or other cancers following the use of a power morcellator during a hysterectomy or fibroid removal procedure may be entitled to compensation. To learn more about filing a morcellator lawsuit, please visit Bernstein Liebhard LLP's website. Free case reviews can also be obtained by calling (888) 340-4807.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorney fees unless their case results in a successful recovery on their behalf. New York State's contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm's fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff's recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
SOURCE Bernstein Liebhard LLP